NOMAD POWER SOLUTIONS, INC.

Loading earnings…

Quarter	Revenue YoY	Gross margin	Cash & equivalents
(Filed on August 14, 2026)	—	—	$12.7M
On June 12, 2026, the company signed a definitive merger agreement to acquire NOMAD Transportable Power Systems, Inc., a provider of deployable, utility-grade battery energy storage systems (BESS), as part of a strategic transformation from biopharmaceutical/proton-therapy operations into AI energy infrastructure. On June 16, 2026, the company advanced $6.5 million to NOMAD under a 15% secured promissory note (first-priority lien on substantially all NOMAD assets) to repay NOMAD's existing bank loan. The merger closed July 1, 2026 (post-quarter); the company was renamed Nomad Power Solutions, Inc. and began trading under ticker NMAD on July 6, 2026. NOMAD is the accounting acquirer under ASC 805 (reverse acquisition). The company committed to advance at least $15.5 million in working capital to NOMAD post-closing; the $6.5 million note was applied against this obligation and the remaining $9 million was funded at closing. The GEIS Phase 1b trial of LB-100 in combination with doxorubicin in advanced soft tissue sarcoma (14 patients enrolled) is being closed out: in February 2026, GEIS informed the company that participating sites had been closed. The company's remaining commitment is approximately $293,000, expected to be incurred through December 31, 2026. Separately, the Netherlands Cancer Institute Phase 1b trial of LB-100 plus atezolizumab in metastatic colorectal cancer (2 patients enrolled since August 2024) is on IRB enrollment hold after two serious adverse events (one patient died of dyspnea/lung toxicity; one fully recovered from fever/aphasia). The company is awaiting completion of the NKI IRB review and cannot predict when or whether the hold will be lifted. The MD Anderson Phase 1b/2 trial (LB-100 + dostarlimab, ovarian clear cell carcinoma) remains active with 21 patients enrolled, expected to complete by December 31, 2027. The LiGHT proton therapy system (acquired via the November 2025 Liora asset acquisition, carried at $6.6 million) remains non-operational at the UKRI Daresbury Laboratory facility. During the six months ended June 30, 2026, the company incurred $529,494 in engineering consulting and $277,899 in other G&A expenses directly related to Liora. The company expects to spend approximately $2 million over the next 24 months to recommission and update the system. No depreciation has been recognized (asset under construction) and no impairment was recorded. A two-year operating lease at approximately $198,500 per quarter (no renewal option) expires within the remaining lease term of 1.38 years. The company completed a registered direct offering on June 2-4, 2026, issuing 2,366,499 common shares and pre-funded warrants for 258,859 shares at $6.31 per share, generating approximately $16.6 million gross ($16.4 million net). This was required by the merger agreement, which mandated at least $16.5 million in unrestricted cash at closing. Cash at June 30, 2026 was $12.7 million (before the post-quarter $9 million working-capital advance to NOMAD). Management issued a going-concern warning, citing no revenue since inception, negative operating cash flows, and anticipated expenditures including the LiGHT recommissioning and clinical trial commitments. During the six months ended June 30, 2026, all 2,423,130 Series B Convertible Preferred shares were converted into common stock (into 2,544,821 shares plus $86,955 accrued dividends), eliminating the preferred class. The Board cancelled 500,000 previously granted stock options and issued 500,000 fully-vested RSUs in replacement (April 15, 2026), recording $383,186 of incremental compensation expense. Total stock-based compensation for the six months was $704,407. Post-quarter, two warrant holders elected cash settlement of 780,726 warrants (approximately $3.98 million) under the fundamental-transaction provision triggered by the board-approved NOMAD merger; the 30-trading-day election window expired August 12, 2026 with no additional elections.
(Filed on May 14, 2026)	—	—	$3.3M
The supplied SEC filing is a Form 10-Q for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) for the quarter ended March 31, 2026, and contains no information pertaining to Nomad Power Solutions, Inc.; therefore no material operational developments for the specified company can be summarized from this document.
(Filed on March 31, 2026)	—	—	$5.1M

(Filed on November 12, 2025)	—	—	$2.9M

(Filed on August 14, 2026)	—	—	$887.2K

(Filed on May 14, 2026)	—	—	$1.4M

(Filed on March 31, 2026)	—	—	$1M

(Filed on November 12, 2025)	—	—	$1.6M

(Filed on August 7, 2025)	—	—	$2.6M

(Filed on May 12, 2025)	—	—	$3.4M

(Filed on March 24, 2025)	—	—	$4.2M

(Filed on November 12, 2024)	-44.7%	0.0%	$5.1M

(Filed on August 8, 2024)	-30.7%	0.0%	$2.9M

(Filed on May 9, 2024)	-8.2%	0.0%	$4.1M

(Filed on March 19, 2024)	—	—	$5.4M

(Filed on November 9, 2023)	—	0.0%	$6.6M

(Filed on August 9, 2023)	—	0.0%	$7.7M

(Filed on May 10, 2023)	—	0.0%	$3.8M

(Filed on March 29, 2023)	—	—	$4.8M

(Filed on November 8, 2022)	—	—	$6M

(Filed on August 10, 2022)	—	—	$6.8M

(Filed on May 11, 2022)	—	—	$7.7M

(Filed on March 21, 2022)	—	—	$5.1M

(Filed on November 10, 2021)	—	—	$1.1M

(Filed on August 10, 2021)	—	—	$1.8M

(Filed on May 12, 2021)	—	—	$2.2M

(Filed on March 26, 2021)	—	—	$2.6M

(Filed on November 10, 2020)	—	—	$3M

(Filed on August 10, 2020)	—	—	$3.6M

(Filed on May 11, 2020)	—	—	$3.9M

(Filed on March 25, 2020)	—	—	$4.3M

(Filed on November 8, 2019)	—	—	$374.4K

(Filed on August 6, 2019)	—	—	$536K

(Filed on May 9, 2019)	—	—	$808K

(Filed on March 25, 2019)	—	—	$1.3M

(Filed on November 8, 2018)	—	—	$1.6M

(Filed on August 2, 2018)	—	—	$2M

(Filed on April 27, 2018)	—	—	$870.9K

(Filed on March 23, 2018)	-97.0%	0.0%	$199.9K

(Filed on November 9, 2017)	0.0%	0.0%	$669.8K

(Filed on August 4, 2017)	0.0%	0.0%	$95.8K

(Filed on May 10, 2017)	0.0%	0.0%	$99.4K

(Filed on March 29, 2017)	—	97.0%	$25.3K

(Filed on November 4, 2016)	—	0.0%	$217.6K

(Filed on August 10, 2016)	—	0.0%	$126.5K

(Filed on May 6, 2016)	0.0%	0.0%	$140.1K

(Filed on March 28, 2016)	—	—	$44.4K

(Filed on November 10, 2015)	—	—	$8.9K

(Filed on August 7, 2015)	—	—	$46.7K

(Filed on May 13, 2015)	—	0.0%	$115.4K

(Filed on March 21, 2014)	—	—	$475K

(Filed on November 7, 2013)	—	—	$791K

(Filed on August 5, 2013)	—	—	$1.1M

(Filed on May 9, 2013)	—	—	$1.4M

(Filed on March 21, 2014)	—	—	$1.7M

(Filed on November 7, 2013)	—	—	$1.9M

(Filed on August 5, 2013)	—	—	$2.2M

(Filed on May 9, 2013)	—	—	$68.7K

(Filed on March 15, 2013)	—	—	$14.3K

(Filed on November 13, 2012)	—	—	$130K

(Filed on August 10, 2012)	—	—	$34.2K

(Filed on May 10, 2012)	—	—	—

(Filed on March 29, 2012)	—	—	$119.1K

(Filed on November 10, 2011)	—	—	—

(Filed on August 12, 2011)	—	—	—

Quarter

Revenue YoY

Gross margin

Cash & equivalents

(Filed on August 14, 2026)

—

$12.7M

On June 12, 2026, the company signed a definitive merger agreement to acquire NOMAD Transportable Power Systems, Inc., a provider of deployable, utility-grade battery energy storage systems (BESS), as part of a strategic transformation from biopharmaceutical/proton-therapy operations into AI energy infrastructure. On June 16, 2026, the company advanced $6.5 million to NOMAD under a 15% secured promissory note (first-priority lien on substantially all NOMAD assets) to repay NOMAD's existing bank loan. The merger closed July 1, 2026 (post-quarter); the company was renamed Nomad Power Solutions, Inc. and began trading under ticker NMAD on July 6, 2026. NOMAD is the accounting acquirer under ASC 805 (reverse acquisition). The company committed to advance at least $15.5 million in working capital to NOMAD post-closing; the $6.5 million note was applied against this obligation and the remaining $9 million was funded at closing.
The GEIS Phase 1b trial of LB-100 in combination with doxorubicin in advanced soft tissue sarcoma (14 patients enrolled) is being closed out: in February 2026, GEIS informed the company that participating sites had been closed. The company's remaining commitment is approximately $293,000, expected to be incurred through December 31, 2026. Separately, the Netherlands Cancer Institute Phase 1b trial of LB-100 plus atezolizumab in metastatic colorectal cancer (2 patients enrolled since August 2024) is on IRB enrollment hold after two serious adverse events (one patient died of dyspnea/lung toxicity; one fully recovered from fever/aphasia). The company is awaiting completion of the NKI IRB review and cannot predict when or whether the hold will be lifted. The MD Anderson Phase 1b/2 trial (LB-100 + dostarlimab, ovarian clear cell carcinoma) remains active with 21 patients enrolled, expected to complete by December 31, 2027.
The LiGHT proton therapy system (acquired via the November 2025 Liora asset acquisition, carried at $6.6 million) remains non-operational at the UKRI Daresbury Laboratory facility. During the six months ended June 30, 2026, the company incurred $529,494 in engineering consulting and $277,899 in other G&A expenses directly related to Liora. The company expects to spend approximately $2 million over the next 24 months to recommission and update the system. No depreciation has been recognized (asset under construction) and no impairment was recorded. A two-year operating lease at approximately $198,500 per quarter (no renewal option) expires within the remaining lease term of 1.38 years.
The company completed a registered direct offering on June 2-4, 2026, issuing 2,366,499 common shares and pre-funded warrants for 258,859 shares at $6.31 per share, generating approximately $16.6 million gross ($16.4 million net). This was required by the merger agreement, which mandated at least $16.5 million in unrestricted cash at closing. Cash at June 30, 2026 was $12.7 million (before the post-quarter $9 million working-capital advance to NOMAD). Management issued a going-concern warning, citing no revenue since inception, negative operating cash flows, and anticipated expenditures including the LiGHT recommissioning and clinical trial commitments.
During the six months ended June 30, 2026, all 2,423,130 Series B Convertible Preferred shares were converted into common stock (into 2,544,821 shares plus $86,955 accrued dividends), eliminating the preferred class. The Board cancelled 500,000 previously granted stock options and issued 500,000 fully-vested RSUs in replacement (April 15, 2026), recording $383,186 of incremental compensation expense. Total stock-based compensation for the six months was $704,407. Post-quarter, two warrant holders elected cash settlement of 780,726 warrants (approximately $3.98 million) under the fundamental-transaction provision triggered by the board-approved NOMAD merger; the 30-trading-day election window expired August 12, 2026 with no additional elections.

(Filed on May 14, 2026)

—

$3.3M

The supplied SEC filing is a Form 10-Q for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) for the quarter ended March 31, 2026, and contains no information pertaining to Nomad Power Solutions, Inc.; therefore no material operational developments for the specified company can be summarized from this document.

(Filed on March 31, 2026)

—

$5.1M

(Filed on November 12, 2025)

—

$2.9M

(Filed on August 14, 2026)

—

$887.2K

(Filed on May 14, 2026)

—

$1.4M

(Filed on March 31, 2026)

—

$1M

(Filed on November 12, 2025)

—

$1.6M

(Filed on August 7, 2025)

—

$2.6M

(Filed on May 12, 2025)

—

$3.4M

(Filed on March 24, 2025)

—

$4.2M

(Filed on November 12, 2024)

-44.7%

0.0%

$5.1M

(Filed on August 8, 2024)

-30.7%

0.0%

$2.9M

(Filed on May 9, 2024)

-8.2%

0.0%

$4.1M

(Filed on March 19, 2024)

—

$5.4M

(Filed on November 9, 2023)

—

0.0%

$6.6M

(Filed on August 9, 2023)

—

0.0%

$7.7M

(Filed on May 10, 2023)

—

0.0%

$3.8M

(Filed on March 29, 2023)

—

$4.8M

(Filed on November 8, 2022)

—

$6M

(Filed on August 10, 2022)

—

$6.8M

(Filed on May 11, 2022)

—

$7.7M

(Filed on March 21, 2022)

—

$5.1M

(Filed on November 10, 2021)

—

$1.1M

(Filed on August 10, 2021)

—

$1.8M

(Filed on May 12, 2021)

—

$2.2M

(Filed on March 26, 2021)

—

$2.6M

(Filed on November 10, 2020)

—

$3M

(Filed on August 10, 2020)

—

$3.6M

(Filed on May 11, 2020)

—

$3.9M

(Filed on March 25, 2020)

—

$4.3M

(Filed on November 8, 2019)

—

$374.4K

(Filed on August 6, 2019)

—

$536K

(Filed on May 9, 2019)

—

$808K

(Filed on March 25, 2019)

—

$1.3M

(Filed on November 8, 2018)

—

$1.6M

(Filed on August 2, 2018)

—

$2M

(Filed on April 27, 2018)

—

$870.9K

(Filed on March 23, 2018)

-97.0%

0.0%

$199.9K

(Filed on November 9, 2017)

0.0%

$669.8K

(Filed on August 4, 2017)

0.0%

$95.8K

(Filed on May 10, 2017)

0.0%

$99.4K

(Filed on March 29, 2017)

—

97.0%

$25.3K

(Filed on November 4, 2016)

—

0.0%

$217.6K

(Filed on August 10, 2016)

—

0.0%

$126.5K

(Filed on May 6, 2016)

0.0%

$140.1K

(Filed on March 28, 2016)

—

$44.4K

(Filed on November 10, 2015)

—

$8.9K

(Filed on August 7, 2015)

—

$46.7K

(Filed on May 13, 2015)

—

0.0%

$115.4K

(Filed on March 21, 2014)

—

$475K

(Filed on November 7, 2013)

—

$791K

(Filed on August 5, 2013)

—

$1.1M

(Filed on May 9, 2013)

—

$1.4M

(Filed on March 21, 2014)

—

$1.7M

(Filed on November 7, 2013)

—

$1.9M

(Filed on August 5, 2013)

—

$2.2M

(Filed on May 9, 2013)

—

$68.7K

(Filed on March 15, 2013)

—

$14.3K

(Filed on November 13, 2012)

—

$130K

(Filed on August 10, 2012)

—

$34.2K

(Filed on May 10, 2012)

—

(Filed on March 29, 2012)

—

$119.1K

(Filed on November 10, 2011)

—

(Filed on August 12, 2011)

—

Quarter	Revenue YoY	Gross margin	Cash & equivalents
(Filed on August 14, 2026)	—	—	$12.7M
On June 12, 2026, the company signed a definitive merger agreement to acquire NOMAD Transportable Power Systems, Inc., a provider of deployable, utility-grade battery energy storage systems (BESS), as part of a strategic transformation from biopharmaceutical/proton-therapy operations into AI energy infrastructure. On June 16, 2026, the company advanced $6.5 million to NOMAD under a 15% secured promissory note (first-priority lien on substantially all NOMAD assets) to repay NOMAD's existing bank loan. The merger closed July 1, 2026 (post-quarter); the company was renamed Nomad Power Solutions, Inc. and began trading under ticker NMAD on July 6, 2026. NOMAD is the accounting acquirer under ASC 805 (reverse acquisition). The company committed to advance at least $15.5 million in working capital to NOMAD post-closing; the $6.5 million note was applied against this obligation and the remaining $9 million was funded at closing. The GEIS Phase 1b trial of LB-100 in combination with doxorubicin in advanced soft tissue sarcoma (14 patients enrolled) is being closed out: in February 2026, GEIS informed the company that participating sites had been closed. The company's remaining commitment is approximately $293,000, expected to be incurred through December 31, 2026. Separately, the Netherlands Cancer Institute Phase 1b trial of LB-100 plus atezolizumab in metastatic colorectal cancer (2 patients enrolled since August 2024) is on IRB enrollment hold after two serious adverse events (one patient died of dyspnea/lung toxicity; one fully recovered from fever/aphasia). The company is awaiting completion of the NKI IRB review and cannot predict when or whether the hold will be lifted. The MD Anderson Phase 1b/2 trial (LB-100 + dostarlimab, ovarian clear cell carcinoma) remains active with 21 patients enrolled, expected to complete by December 31, 2027. The LiGHT proton therapy system (acquired via the November 2025 Liora asset acquisition, carried at $6.6 million) remains non-operational at the UKRI Daresbury Laboratory facility. During the six months ended June 30, 2026, the company incurred $529,494 in engineering consulting and $277,899 in other G&A expenses directly related to Liora. The company expects to spend approximately $2 million over the next 24 months to recommission and update the system. No depreciation has been recognized (asset under construction) and no impairment was recorded. A two-year operating lease at approximately $198,500 per quarter (no renewal option) expires within the remaining lease term of 1.38 years. The company completed a registered direct offering on June 2-4, 2026, issuing 2,366,499 common shares and pre-funded warrants for 258,859 shares at $6.31 per share, generating approximately $16.6 million gross ($16.4 million net). This was required by the merger agreement, which mandated at least $16.5 million in unrestricted cash at closing. Cash at June 30, 2026 was $12.7 million (before the post-quarter $9 million working-capital advance to NOMAD). Management issued a going-concern warning, citing no revenue since inception, negative operating cash flows, and anticipated expenditures including the LiGHT recommissioning and clinical trial commitments. During the six months ended June 30, 2026, all 2,423,130 Series B Convertible Preferred shares were converted into common stock (into 2,544,821 shares plus $86,955 accrued dividends), eliminating the preferred class. The Board cancelled 500,000 previously granted stock options and issued 500,000 fully-vested RSUs in replacement (April 15, 2026), recording $383,186 of incremental compensation expense. Total stock-based compensation for the six months was $704,407. Post-quarter, two warrant holders elected cash settlement of 780,726 warrants (approximately $3.98 million) under the fundamental-transaction provision triggered by the board-approved NOMAD merger; the 30-trading-day election window expired August 12, 2026 with no additional elections.
(Filed on May 14, 2026)	—	—	$3.3M
The supplied SEC filing is a Form 10-Q for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) for the quarter ended March 31, 2026, and contains no information pertaining to Nomad Power Solutions, Inc.; therefore no material operational developments for the specified company can be summarized from this document.
(Filed on March 31, 2026)	—	—	$5.1M

(Filed on November 12, 2025)	—	—	$2.9M

(Filed on August 14, 2026)	—	—	$887.2K

(Filed on May 14, 2026)	—	—	$1.4M

(Filed on March 31, 2026)	—	—	$1M

(Filed on November 12, 2025)	—	—	$1.6M

(Filed on August 7, 2025)	—	—	$2.6M

(Filed on May 12, 2025)	—	—	$3.4M

(Filed on March 24, 2025)	—	—	$4.2M

(Filed on November 12, 2024)	-44.7%	0.0%	$5.1M

(Filed on August 8, 2024)	-30.7%	0.0%	$2.9M

(Filed on May 9, 2024)	-8.2%	0.0%	$4.1M

(Filed on March 19, 2024)	—	—	$5.4M

(Filed on November 9, 2023)	—	0.0%	$6.6M

(Filed on August 9, 2023)	—	0.0%	$7.7M

(Filed on May 10, 2023)	—	0.0%	$3.8M

(Filed on March 29, 2023)	—	—	$4.8M

(Filed on November 8, 2022)	—	—	$6M

(Filed on August 10, 2022)	—	—	$6.8M

(Filed on May 11, 2022)	—	—	$7.7M

(Filed on March 21, 2022)	—	—	$5.1M

(Filed on November 10, 2021)	—	—	$1.1M

(Filed on August 10, 2021)	—	—	$1.8M

(Filed on May 12, 2021)	—	—	$2.2M

(Filed on March 26, 2021)	—	—	$2.6M

(Filed on November 10, 2020)	—	—	$3M

(Filed on August 10, 2020)	—	—	$3.6M

(Filed on May 11, 2020)	—	—	$3.9M

(Filed on March 25, 2020)	—	—	$4.3M

(Filed on November 8, 2019)	—	—	$374.4K

(Filed on August 6, 2019)	—	—	$536K

(Filed on May 9, 2019)	—	—	$808K

(Filed on March 25, 2019)	—	—	$1.3M

(Filed on November 8, 2018)	—	—	$1.6M

(Filed on August 2, 2018)	—	—	$2M

(Filed on April 27, 2018)	—	—	$870.9K

(Filed on March 23, 2018)	-97.0%	0.0%	$199.9K

(Filed on November 9, 2017)	0.0%	0.0%	$669.8K

(Filed on August 4, 2017)	0.0%	0.0%	$95.8K

(Filed on May 10, 2017)	0.0%	0.0%	$99.4K

(Filed on March 29, 2017)	—	97.0%	$25.3K

(Filed on November 4, 2016)	—	0.0%	$217.6K

(Filed on August 10, 2016)	—	0.0%	$126.5K

(Filed on May 6, 2016)	0.0%	0.0%	$140.1K

(Filed on March 28, 2016)	—	—	$44.4K

(Filed on November 10, 2015)	—	—	$8.9K

(Filed on August 7, 2015)	—	—	$46.7K

(Filed on May 13, 2015)	—	0.0%	$115.4K

(Filed on March 21, 2014)	—	—	$475K

(Filed on November 7, 2013)	—	—	$791K

(Filed on August 5, 2013)	—	—	$1.1M

(Filed on May 9, 2013)	—	—	$1.4M

(Filed on March 21, 2014)	—	—	$1.7M

(Filed on November 7, 2013)	—	—	$1.9M

(Filed on August 5, 2013)	—	—	$2.2M

(Filed on May 9, 2013)	—	—	$68.7K

(Filed on March 15, 2013)	—	—	$14.3K

(Filed on November 13, 2012)	—	—	$130K

(Filed on August 10, 2012)	—	—	$34.2K

(Filed on May 10, 2012)	—	—	—

(Filed on March 29, 2012)	—	—	$119.1K

(Filed on November 10, 2011)	—	—	—

(Filed on August 12, 2011)	—	—	—

Quarter

Revenue YoY

Gross margin

Cash & equivalents

(Filed on August 14, 2026)

—

$12.7M

On June 12, 2026, the company signed a definitive merger agreement to acquire NOMAD Transportable Power Systems, Inc., a provider of deployable, utility-grade battery energy storage systems (BESS), as part of a strategic transformation from biopharmaceutical/proton-therapy operations into AI energy infrastructure. On June 16, 2026, the company advanced $6.5 million to NOMAD under a 15% secured promissory note (first-priority lien on substantially all NOMAD assets) to repay NOMAD's existing bank loan. The merger closed July 1, 2026 (post-quarter); the company was renamed Nomad Power Solutions, Inc. and began trading under ticker NMAD on July 6, 2026. NOMAD is the accounting acquirer under ASC 805 (reverse acquisition). The company committed to advance at least $15.5 million in working capital to NOMAD post-closing; the $6.5 million note was applied against this obligation and the remaining $9 million was funded at closing.
The GEIS Phase 1b trial of LB-100 in combination with doxorubicin in advanced soft tissue sarcoma (14 patients enrolled) is being closed out: in February 2026, GEIS informed the company that participating sites had been closed. The company's remaining commitment is approximately $293,000, expected to be incurred through December 31, 2026. Separately, the Netherlands Cancer Institute Phase 1b trial of LB-100 plus atezolizumab in metastatic colorectal cancer (2 patients enrolled since August 2024) is on IRB enrollment hold after two serious adverse events (one patient died of dyspnea/lung toxicity; one fully recovered from fever/aphasia). The company is awaiting completion of the NKI IRB review and cannot predict when or whether the hold will be lifted. The MD Anderson Phase 1b/2 trial (LB-100 + dostarlimab, ovarian clear cell carcinoma) remains active with 21 patients enrolled, expected to complete by December 31, 2027.
The LiGHT proton therapy system (acquired via the November 2025 Liora asset acquisition, carried at $6.6 million) remains non-operational at the UKRI Daresbury Laboratory facility. During the six months ended June 30, 2026, the company incurred $529,494 in engineering consulting and $277,899 in other G&A expenses directly related to Liora. The company expects to spend approximately $2 million over the next 24 months to recommission and update the system. No depreciation has been recognized (asset under construction) and no impairment was recorded. A two-year operating lease at approximately $198,500 per quarter (no renewal option) expires within the remaining lease term of 1.38 years.
The company completed a registered direct offering on June 2-4, 2026, issuing 2,366,499 common shares and pre-funded warrants for 258,859 shares at $6.31 per share, generating approximately $16.6 million gross ($16.4 million net). This was required by the merger agreement, which mandated at least $16.5 million in unrestricted cash at closing. Cash at June 30, 2026 was $12.7 million (before the post-quarter $9 million working-capital advance to NOMAD). Management issued a going-concern warning, citing no revenue since inception, negative operating cash flows, and anticipated expenditures including the LiGHT recommissioning and clinical trial commitments.
During the six months ended June 30, 2026, all 2,423,130 Series B Convertible Preferred shares were converted into common stock (into 2,544,821 shares plus $86,955 accrued dividends), eliminating the preferred class. The Board cancelled 500,000 previously granted stock options and issued 500,000 fully-vested RSUs in replacement (April 15, 2026), recording $383,186 of incremental compensation expense. Total stock-based compensation for the six months was $704,407. Post-quarter, two warrant holders elected cash settlement of 780,726 warrants (approximately $3.98 million) under the fundamental-transaction provision triggered by the board-approved NOMAD merger; the 30-trading-day election window expired August 12, 2026 with no additional elections.

(Filed on May 14, 2026)

—

$3.3M

The supplied SEC filing is a Form 10-Q for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) for the quarter ended March 31, 2026, and contains no information pertaining to Nomad Power Solutions, Inc.; therefore no material operational developments for the specified company can be summarized from this document.

(Filed on March 31, 2026)

—

$5.1M

(Filed on November 12, 2025)

—

$2.9M

(Filed on August 14, 2026)

—

$887.2K

(Filed on May 14, 2026)

—

$1.4M

(Filed on March 31, 2026)

—

$1M

(Filed on November 12, 2025)

—

$1.6M

(Filed on August 7, 2025)

—

$2.6M

(Filed on May 12, 2025)

—

$3.4M

(Filed on March 24, 2025)

—

$4.2M

(Filed on November 12, 2024)

-44.7%

0.0%

$5.1M

(Filed on August 8, 2024)

-30.7%

0.0%

$2.9M

(Filed on May 9, 2024)

-8.2%

0.0%

$4.1M

(Filed on March 19, 2024)

—

$5.4M

(Filed on November 9, 2023)

—

0.0%

$6.6M

(Filed on August 9, 2023)

—

0.0%

$7.7M

(Filed on May 10, 2023)

—

0.0%

$3.8M

(Filed on March 29, 2023)

—

$4.8M

(Filed on November 8, 2022)

—

$6M

(Filed on August 10, 2022)

—

$6.8M

(Filed on May 11, 2022)

—

$7.7M

(Filed on March 21, 2022)

—

$5.1M

(Filed on November 10, 2021)

—

$1.1M

(Filed on August 10, 2021)

—

$1.8M

(Filed on May 12, 2021)

—

$2.2M

(Filed on March 26, 2021)

—

$2.6M

(Filed on November 10, 2020)

—

$3M

(Filed on August 10, 2020)

—

$3.6M

(Filed on May 11, 2020)

—

$3.9M

(Filed on March 25, 2020)

—

$4.3M

(Filed on November 8, 2019)

—

$374.4K

(Filed on August 6, 2019)

—

$536K

(Filed on May 9, 2019)

—

$808K

(Filed on March 25, 2019)

—

$1.3M

(Filed on November 8, 2018)

—

$1.6M

(Filed on August 2, 2018)

—

$2M

(Filed on April 27, 2018)

—

$870.9K

(Filed on March 23, 2018)

-97.0%

0.0%

$199.9K

(Filed on November 9, 2017)

0.0%

$669.8K

(Filed on August 4, 2017)

0.0%

$95.8K

(Filed on May 10, 2017)

0.0%

$99.4K

(Filed on March 29, 2017)

—

97.0%

$25.3K

(Filed on November 4, 2016)

—

0.0%

$217.6K

(Filed on August 10, 2016)

—

0.0%

$126.5K

(Filed on May 6, 2016)

0.0%

$140.1K

(Filed on March 28, 2016)

—

$44.4K

(Filed on November 10, 2015)

—

$8.9K

(Filed on August 7, 2015)

—

$46.7K

(Filed on May 13, 2015)

—

0.0%

$115.4K

(Filed on March 21, 2014)

—

$475K

(Filed on November 7, 2013)

—

$791K

(Filed on August 5, 2013)

—

$1.1M

(Filed on May 9, 2013)

—

$1.4M

(Filed on March 21, 2014)

—

$1.7M

(Filed on November 7, 2013)

—

$1.9M

(Filed on August 5, 2013)

—

$2.2M

(Filed on May 9, 2013)

—

$68.7K

(Filed on March 15, 2013)

—

$14.3K

(Filed on November 13, 2012)

—

$130K

(Filed on August 10, 2012)

—

$34.2K

(Filed on May 10, 2012)

—

(Filed on March 29, 2012)

—

$119.1K

(Filed on November 10, 2011)

—

(Filed on August 12, 2011)

—